loading page

Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients with Chronic Hepatitis C Virus Infection
  • +5
  • Xiao-duo Guan,
  • Xian-ge Tang,
  • Ying-jun Zhang,
  • Hong-ming Xie,
  • Lin Luo,
  • Dan Wu,
  • Rui Chen,
  • Pei Hu
Xiao-duo Guan
Chinese Academy of Medical Sciences and Peking Union Medical College
Author Profile
Xian-ge Tang
Chinese Academy of Medical Sciences and Peking Union Medical College
Author Profile
Ying-jun Zhang
Author Profile
Hong-ming Xie
Author Profile
Rui Chen
Chinese Academy of Medical Sciences and Peking Union Medical College
Author Profile
Pei Hu
Chinese Academy of Medical Sciences and Peking Union Medical College
Author Profile

Abstract

Aims Yimitasvir is a novel, oral hepatitis C virus (HCV) non-structural protein 5A inhibitor for the treatment of chronic HCV genotype 1 infection. The objective of this analysis was to develop a population pharmacokinetic model of yimitasvir in Chinese healthy volunteers and HCV infection patients. Methods The model was performed using data from 219 subjects across 6 studies. Nonlinear mixed effects models were developed using Phoenix NLME software. The covariates were evaluated using a stepwise forward inclusion (P < 0.01) and then a backward exclusion procedure (P < 0.001). Results A two-compartment model with sequential zero-first order absorption and first-order elimination reasonably described yimitasvir pharmacokinetics (PK). The apparent oral clearance and central volume of distribution were 13.8 l h-1 and 188 l, respectively. The bioavailability (F) of yimitasvir decreased 12.9% for each 100 mg dose increase. Food was found to affect absorption rate (Ka) and F. High-fat meal decreased Ka and F by 90.9% and 38.5%, respectively. Gender and alanine aminotransferase were identified as significant covariates on apparent oral clearance. Female subjects had lower clearance than male subjects. Zero-order absorption duration was longer in healthy volunteers (2.17 h) than that in patients (1.43 h). Conclusions The population pharmacokinetic model described yimitasvir PK profile well. Food decreased Ka and F significantly, so it was recommended to take yimitasvir at least 2 h before or after a meal. Other significant covariates were not clinically important.

Peer review status:Published

28 Jan 2021Published in Frontiers in Pharmacology volume 11. 10.3389/fphar.2020.617122